| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 01/09/2002 | EP1169320A1 Farnesyl transferase inhibitors having a pyrrole structure and process for preparation thereof |
| 01/09/2002 | EP1169317A1 Triarylimidazoles |
| 01/09/2002 | EP1169316A1 Novel lipoic acid derivatives, their preparation, and pharmaceutical compositions containing them |
| 01/09/2002 | EP1169313A2 1,4-benzothiazepine-1,1-dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof |
| 01/09/2002 | EP1169306A1 Dibenzoazulene derivatives for treating thrombosis, osteoporosis, arteriosclerosis |
| 01/09/2002 | EP1169302A1 N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists |
| 01/09/2002 | EP1169298A2 Pharmaceutical compounds |
| 01/09/2002 | EP1169244A2 Metering valve |
| 01/09/2002 | EP1169060A1 Sodium channel blocker compositions and the use thereof |
| 01/09/2002 | EP1169058A1 Insulin-like growth factor binding protein-4 protease |
| 01/09/2002 | EP1169054A2 Products and methods for treating ptp lar related diseases |
| 01/09/2002 | EP1169043A1 Use of estrogens and delta-gonadien-21-ol-3,20-diones |
| 01/09/2002 | EP1169042A1 Dibenzo-azepine derivatives as alpha v integrin receptor antagonists |
| 01/09/2002 | EP1169038A1 Cyclic protein tyrosine kinase inhibitors |
| 01/09/2002 | EP1169025A2 Transdermal drug delivery devices comprising a polyurethane drug reservoir |
| 01/09/2002 | EP1169005A2 Association of no-synthase inhibitor(s) and metabolic antioxidant(s) |
| 01/09/2002 | EP1168919A2 Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) and surfactant depletion |
| 01/09/2002 | EP1168917A2 Human lung cancer associated gene sequences and polypeptides |
| 01/09/2002 | EP0970042B1 5-hydroxymethyl-2-aminotetralins as cardiovascular agents |
| 01/09/2002 | EP0607439B1 Nitrogenous heterocyclic compound |
| 01/09/2002 | CN1330661A Procollagen C-proteinase inhibitors |
| 01/09/2002 | CN1330655A Fused 1,2,4-thiadiazine derivatives, their preparation and use |
| 01/09/2002 | CN1330642A N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, irreversible inihibotr of tyrosine kinases |
| 01/09/2002 | CN1330640A Cyclic hydrazine derivatives as TNF-alpha inhibitors |
| 01/09/2002 | CN1330638A Substituted benzo (de) isoquinoline-1,3-diones |
| 01/09/2002 | CN1330631A Amide derivatives which are useful as cell factor inhibitors |
| 01/09/2002 | CN1330556A Combination therepy of angiotensin-converting enzyme inhibor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease |
| 01/09/2002 | CN1330555A Antibodies to truncated VEGF-D and uses thereof |
| 01/09/2002 | CN1330549A Method for preventing and reversing atherosclerosis in mammals |
| 01/09/2002 | CN1330548A Phospholipid complexes of proanthocyanidin A2 used as antiatherosclerotic agents |
| 01/09/2002 | CN1330543A Compositions and methods for amelioration of human female sexual dysfunction |
| 01/09/2002 | CN1330539A Compositions and methods for treatment of anorectal disorders |
| 01/09/2002 | CN1330536A Biodegradable polymer encapsulated 5-hydroxytryptamine receptor antagonist and method for preparing the same |
| 01/09/2002 | CN1330075A Endothelin antagon |
| 01/09/2002 | CN1330069A Substituted 2-benzo [c] furanone compound, its preparing process and medicinal composition containing it |
| 01/09/2002 | CN1329911A Health-care medicinal liquor |
| 01/09/2002 | CN1329891A Vascular formation inhibitor |
| 01/09/2002 | CN1329888A Method for preparing medicine containing substitution pyridyl dihydric heptene acid or it salt |
| 01/09/2002 | CN1077568C Phenoxyphenyl cyclopentenyl hydroxyureas |
| 01/09/2002 | CN1077431C Mediodespidine |
| 01/08/2002 | US6337411 Muscular disorders |
| 01/08/2002 | US6337397 Pyrimidine derivatives and their salts, useful for making benzoxazepine derivatives |
| 01/08/2002 | US6337350 Inhibitors of formation of advanced glycation endproducts (AGEs) |
| 01/08/2002 | US6337344 Anticoagulants and enzyme inhibitors for cardiovascular disorders |
| 01/08/2002 | CA2205202C Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
| 01/08/2002 | CA2161805C An exercise hydration regimen to enhance exercise endurance and performance |
| 01/08/2002 | CA2159915C Systemic effects of nitric oxide inhalation |
| 01/03/2002 | WO2002000887A1 Novel therapeutic molecular variants and uses thereof |
| 01/03/2002 | WO2002000873A1 Human site-1 protease promoter |
| 01/03/2002 | WO2002000860A2 Novel proteases |
| 01/03/2002 | WO2002000850A1 Method of preparing heart muscle cells and method of searching for remedy for heart diseases |
| 01/03/2002 | WO2002000728A2 Methods and compositions for isolating biologically active antibodies |
| 01/03/2002 | WO2002000725A2 G-protein coupled receptor org10 |
| 01/03/2002 | WO2002000710A2 B7-like molecules and uses thereof |
| 01/03/2002 | WO2002000691A2 Polynucleotides and polypeptides encoded thereby |
| 01/03/2002 | WO2002000690A2 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| 01/03/2002 | WO2002000680A2 Cationic steroid derivatives for gene delivery |
| 01/03/2002 | WO2002000676A1 Purine derivatives |
| 01/03/2002 | WO2002000664A1 2-aminoalkyl-thieno[2,3-d]pyrimidines |
| 01/03/2002 | WO2002000661A1 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS |
| 01/03/2002 | WO2002000660A1 5-aminoalkyl-pyrazolo[4,3-d]pyrimidines with a phosphodiesterase v-inhibiting effect |
| 01/03/2002 | WO2002000658A1 Cyclic gmp-specific phosphodiesterase inhibitors |
| 01/03/2002 | WO2002000657A2 Condensed pyrazindione derivatives |
| 01/03/2002 | WO2002000656A2 Pirazino '1$m(1)2$m(1) :1, 6! pyrido '3,4-b! indole derivatives |
| 01/03/2002 | WO2002000638A2 Substituted phthalides as anti-convulsive drugs |
| 01/03/2002 | WO2002000633A1 Quinolinyl and benzothiazolyl ppar-gamma modulators |
| 01/03/2002 | WO2002000630A1 Polymorphic forms/hydrates of n-[4-(3-chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)-quinazolin-6-yl]-acrylamide dihydrochloride |
| 01/03/2002 | WO2002000629A1 Iminopyrimidine nmda nr2b receptor antagonists |
| 01/03/2002 | WO2002000621A1 Compounds exhibiting x-type spla2 inhibiting effect |
| 01/03/2002 | WO2002000611A2 Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists |
| 01/03/2002 | WO2002000258A1 Medicinal compositions for angiogenic therapy |
| 01/03/2002 | WO2002000237A1 Therapeutical use of sophora flavescens or sophora subprostrata extracts |
| 01/03/2002 | WO2002000236A1 Extracts from sophora species, method for producing the same and their use |
| 01/03/2002 | WO2002000235A1 A composition made of chinese medicinal herbs for treatment of coronary heart disease and angina pectoris and the process for the production thereof |
| 01/03/2002 | WO2002000234A1 A pharmaceutical preparation of chinese herbs for preventing and treating cardiovascular and cerebrovascular disease and the use thereof |
| 01/03/2002 | WO2002000225A1 7-hydroxyepiandrosterone having neuroprotective activity |
| 01/03/2002 | WO2002000220A1 A method for treating septic shock |
| 01/03/2002 | WO2002000217A1 Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators |
| 01/03/2002 | WO2002000216A1 Carvedilol |
| 01/03/2002 | WO2002000212A1 Controlled release arginine formulations |
| 01/03/2002 | WO2002000210A2 Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease |
| 01/03/2002 | WO2002000203A1 Topical pharmaceutical formulations and methods of treatment |
| 01/03/2002 | WO2002000175A2 Enhancing therapeutic effectiveness of nitric oxide inhalation |
| 01/03/2002 | WO2002000172A2 Methods for using tetanus toxin for benificial purposes in animals (mammals) |
| 01/03/2002 | WO2002000167A2 Modified forms of pharmacologically active agents and uses therefor |
| 01/03/2002 | WO2002000017A2 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5 |
| 01/03/2002 | WO2001072669A3 Therapeutic use of polyhydroxy amine derivates |
| 01/03/2002 | WO2001070693A3 Difluorobutyric acid derivatives and their use as metalloprotease inhibitors |
| 01/03/2002 | WO2001066544A3 Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers |
| 01/03/2002 | WO2001062233A3 Adenosine receptor modulators |
| 01/03/2002 | WO2001053344A3 Chondromodulin-i related peptide |
| 01/03/2002 | WO2001051473A8 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation |
| 01/03/2002 | WO2001043734A3 Transdermal administration of phenylpropanolamine |
| 01/03/2002 | WO2001042265A3 N6 heterocyclic 8-modified adenosine derivatives |
| 01/03/2002 | WO2001032877A3 CpG RECEPTOR (CpG-R) AND METHODS RELATING THERETO |
| 01/03/2002 | WO2001021218A3 Method for determining viability of a myocardial segment |
| 01/03/2002 | WO2001019381A8 An antioxidant preparation based on plant extracts for the treatment of circulation and chronic degenerative problems and of hypertension |
| 01/03/2002 | WO2000061171A9 Uses of mammalian ox2 protein and related reagents |
| 01/03/2002 | US20020002296 Cytoprotective Compounds |
| 01/03/2002 | US20020002269 Artemin, a neurotrophic factor |